



HU000030292T2

(19) **HU**(11) Lajstromszám: **E 030 292**(13) **T2****MAGYARORSZÁG****Szellemi Tulajdon Nemzeti Hivatala**

EURÓPAI SZABADALOM SZÖVEGÉNEK FORDÍTÁSA

(21) Magyar ügyszám: **E 11 829283**(22) A bejelentés napja: **2011. 09. 29.**

(96) Az európai bejelentés bejelentési száma:

EP 20110829283

(97) Az európai bejelentés közzétételi adatai:

EP 2623507 A1 **2012. 04. 05.**

(97) Az európai szabadalom megadásának meghirdetési adatai:

EP 2623507 B1 **2016. 11. 02.**(51) Int. Cl.: **C07F 9/24**

(2006.01)

C07D 473/18

(2006.01)

C07F 965/58

(2006.01)

C07F 965/61

(2006.01)

C07F 7/18

(2006.01)

(86) A nemzetközi (PCT) bejelentési szám:

PCT/JP 11/072407

(87) A nemzetközi közzétételi szám:

WO 12043730

(30) Elsőbbségi adatok:

2010220865**2010. 09. 30.****JP**

(72) Feltaláló(k):

UEDA, Toshihiro, Tsukuba-shilbaraki 305-0003 (JP)

(73) Jogosult(ak):

**Nippon Shinyaku Co., Ltd., Kyoto-shi Kyoto
601-8550 (JP)**

(74) Képviselő:

SBGK Szabadalmi Ügyvivői Iroda, Budapest

(54)

Morfolino-nukleinsav származékok

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.

(19)



(11)

EP 2 623 507 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:

02.11.2016 Bulletin 2016/44

(51) Int Cl.:

C07F 9/24 (2006.01)

C07F 7/18 (2006.01)

C07F 9/6561 (2006.01)

C07D 473/18 (2006.01)

C07F 9/6558 (2006.01)

(21) Application number: **11829283.8**

(86) International application number:

PCT/JP2011/072407

(22) Date of filing: **29.09.2011**

(87) International publication number:

WO 2012/043730 (05.04.2012 Gazette 2012/14)

(54) **MORPHOLINO NUCLEIC ACID DERIVATIVE**

MORPHOLIN-NUKLEINSÄUREDERIVAT

DÉRIVÉ D'ACIDE MORPHOLINO NUCLÉIQUE

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(56) References cited:

**WO-A1-2009/064471 JP-A- 2005 255 530
US-A1- 2009 131 624**

(30) Priority: **30.09.2010 JP 2010220865**

(43) Date of publication of application:

07.08.2013 Bulletin 2013/32

(73) Proprietor: **Nippon Shinyaku Co., Ltd.**

Kyoto-shi

Kyoto 601-8550 (JP)

(72) Inventor: **UEDA, Toshihiro**

Tsukuba-shi

Ibaraki 305-0003 (JP)

(74) Representative: **Vossius & Partner**

Patentanwälte Rechtsanwälte mbB

Siebertstrasse 3

81675 München (DE)

- GAFFNEY B.L. ET AL.: 'A NEW STRATEGY FOR THE PROTECTION OF DEOXYGUANOSINE DURING OLIGONUCLEOTIDE SYNTHESIS' TETRAHEDRON LETTERS vol. 23, no. 22, 1982, pages 2257 - 2260, XP055084717
- KADOKURA M. ET AL.: 'Synthesis of 4-Thiouridine, 6-Thiioinosine, and 6-Thioguanosine 3',5'-O-Bisphosphates as Donor Molecules for RNA Ligation and Their Application to the Synthesis of Photoactivatable TMG-Capped U1 snRNA Fragments' J. ORG. CHEM. vol. 65, no. 17, 2000, pages 5104 - 5113, XP003026454
- ANDREI P. GUZNEV ET AL: "A novel protecting strategy for internucleosidic phosphate and phosphorothioate groups", NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS, vol. 20, no. 4-7, 2001, pages 1011-1014,

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 623 507 B1

Description

[Technical Field]

5 **[0001]** The present invention is directed to the subject-matter according to the claims.

[Background Art]

10 **[0002]** A morpholino nucleic acid monomer whose base moiety is a guanine (hereinafter referred to as a "G monomer") has an oxygen atom bound to the carbon atom in the 6-position of the guanine. Accordingly, when a morpholino nucleic acid oligomer is synthesized using a G monomer whose hydroxy group in the 6-position of the guanine is not protected, a side reaction occurs. For example, in a condensation process, the hydroxy group in the 6-position of the guanine may react with the activated site of other morpholino nucleic acid monomer to form a phosphorylated form, which may then react with ammonia used in a deprotection process, resulting in a conversion from the guanine to a diaminopurine. Such a side reaction serves as a substantial cause of a reduction in the synthesis yield of an intended substance.

15 **[0003]** For the purpose of suppressing the aforementioned side reaction, AVI BioPharma Inc. reported a G monomer whose hydroxy group in the 6-position of the guanine is protected by a pivaloyloxybenzyl group (POB group) (for example, see Patent Document 1). Nevertheless, the POB group is converted during the deprotection process into 4-methylene-cyclohexa-2,5-dienone, which is added to an NH moiety of the morpholine in the morpholino nucleic acid oligomer to form a by-product.

20 **[0004]** In addition, Patent Document 1 includes a description of other protecting groups for the hydroxy group in the 6-position of the guanine. Such other protecting groups disclosed in Patent Document 1 include, for example, 4-nitrophenethyl, phenylsulfonylethyl and methylsulfonylethyl. These protecting groups, however, undergo conversion during the deprotection process to reactive species such as 4-nitrostyrene, which is added to an NH moiety of the morpholine in the morpholino nucleic acid oligomer to form a by-product. While a silyl-type protecting group such as t-butyldimethylsilyl is also known, it has been reported to undergo a side reaction similar to that of the G monomer whose hydroxy group in the 6-position of the guanine is not protected, since it is not stable and tends to be cleaved easily under a morpholino nucleic acid oligomer synthesis condition. Furthermore, a phenyl ether-type protecting group and a carbamate-type protecting group are also known, but it is reported about these protecting group that a detachment of the protecting group is imperfect in the deprotection process or that condensation efficiency turns worse in the condensation process. [Prior art documents]

[Patent Documents]

35 **[0005]** [Patent Document 1] WO2009/064471 A1

[Summary of the Invention]

[Problem to be resolved by the Invention]

40 **[0006]** A mainly object of the invention is to provide a novel morpholino nucleic acid derivative for synthesizing a morpholino nucleic acid oligomer efficiently and a starting material for this derivative.


[Means of solving the Problem]

45 **[0007]** Applicants discovered that a compound represented by the following general formula (1) (hereinafter referred to as a "compound of the invention") or a salt thereof is useful as a starting material for synthesis of a morpholino nucleic acid oligomer or a starting material for obtaining such a starting material for synthesis, thus establishing the present invention.

50

[C.1]


55



(1)

wherein R¹ represents hydrogen or a group represented by the following general formula (2).

[C.2]




(2)


wherein * represents the binding position. R¹¹, R¹², R¹³ are the same or different and each represents hydrogen, alkyl or alkoxy.

R² represents a group represented by the following general formula (3) or (4).

[C.3]



(3)




(4)

wherein * is defined as described above. R⁴ represents alkyl, arylmethyl or aryloxymethyl.

R⁵, R⁶ are the same or different and each represents alkyl. R³ represents a hydroxy group which may be protected by trialkylsilyl or diphenylalkylsilyl, or a group represented by the following formula (5).

[C.4]



(5)

wherein * is defined as described above. X represents O or S.

Y represents dialkylamino or alkoxy.

Z represents halogen.

[0008] Those which can be exemplified as being encompassed by the present invention are the compound of the

invention or a salt thereof.

[0009] Hereinafter, the terms used in the present specification is described in detail.

[0010] The alkyl can include a straight or branched alkyl having 1 to 8 carbon atoms. Specific examples can include methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, *n*-pentyl, isopentyl, *n*-hexyl, isohexyl, *n*-heptyl, isoheptyl and *n*-octyl. Among others, an alkyl having 1 to 6 carbon atoms is preferred, and an alkyl having 1 to 3 carbon atom is more preferred.

[0011] The "alkyl" moiety of "trialkylsilyl", "diphenylalkylsilyl", and dialkylamino" can be exemplified by the same ones as the above "alkyl".

[0012] The "aryl" moiety of "arylmethyl", "aryloxymethyl", and "arylsulfonyl" can include an aryl having 6 to 10 carbon atoms. Specific examples can include phenyl, 1-naphthyl and 2-naphthyl. Among others, phenyl is preferred.

[0013] The alkoxy can include a straight or branched alkoxy having 1 two 8 carbon atoms Such as methoxy, ethoxy, *n*-propoxy, isopropoxy, *n*-butoxy, isobutoxy, *sec*-butoxy, *tert*-butoxy, *n*-pentyloxy, *n*-hexyloxy, *n*-heptyloxy, and *n*-octyloxy.

[0014] The halogen can include fluorine, chlorine, bromine and iodine. Among others, chlorine is preferred.

[0015] The acyl can include a straight or branched alkanoyl or aroyl. Examples of the alkanoyl can include formyl, acetyl, 2-methylacetyl, 2,2-dimethylacetyl, propionyl, butyryl, isobutyryl, pentanoyl, 2,2-dimethylpropionyl, and hexanoyl. Examples of the aroyl can include benzoyl, toluoyl and naphthoyl. The aroyl may optionally be substituted at substitutable positions and may be substituted with an alkyl(s).

[0016] The nucleobase can include adenine, guanine, hypoxanthine, cytosine, thymine, uracil, and modified bases thereof. Examples of such modified nucleobases can include, but not limited to, pseudouracil, 3-methyluracil, dihydrou-
racil, 5-alkylcytosines (e.g., 5-methylcytosine), 5-alkyluracils (e.g., 5-ethyluracil), 5-halouracils (5-bromouracil), 6-aza-
pyrimidine, 6-alkylpyrimidines (6-methyluracil), 2-thiouracil, 4-thiouracil, 4-acetylcytosine, 5-(carboxyhydroxymethyl)
uracil, 5'-carboxymethylaminomethyl-2-thiouracil,
5-carboxymethylaminomethyluracil, 1-methyladenine, 1-methylhypoxanthine, 2,2-dimethylguanine, 3-methylcytosine,
2-methyladenine, 2-methylguanine, N⁶-methyladenine, 7-methylguanine, 5-methoxyaminomethyl-2-thiouracil, 5-meth-
ylaminomethyluracil, 5-methylcarbonylmethyluracil, 5-methyloxyuracil, 5-methyl-2-thiouracil, 2-methylthio-N⁶-isopente-
nyl-adenine, uracil-5-oxyacetic acid, 2-thiocytosine, purine, 2,6-diaminopurine, 2-aminopurine, isoguanine, indole, imi-
dazole, and xanthine.

[0017] Among the compound of the invention, the following compound (a) to (c) or salt thereof is preferable.

- (a) N⁹-[(2R,6S)-6-((*tert*-butyldimethylsilyloxy)methyl)-4-trityl morpholin-2-yl]-N²-(phenoxyacetyl)-O⁶-(2-cyanoethyl)guani ne,
- (b) N⁹-{(2R)-hydroxymethyl-4-tritylmorpholin-2-yl}-N²-(ph enoxyacetyl)-O⁶-(2-cyanoethyl)guanine,
- (c) [(2S,6R)-6-{N²-(phenoxyacetyl)-O⁶-(2-cyanoethyl)guanin-9-y 1}-4--tritylmorpholin-2-yl]methyl
dimethylphosphoramidochloridate.

[Brief Description of the Drawings]

[0018]

Figure 1 shows an HPLC chromatographic chart of a crude morpholino nucleic acid oligomer synthesized using a CE-G monomer (for definition, see Table 1). The ordinate represents the intensity (mAU), while the abscissa represents the retention time (minutes).

Figure 2 shows an HPJC chromatographic chart of a crude morpholino nucleic acid oligomer synthesized using a POB-G monomer (for definition, see Table 1) . The ordinate represents the intensity (mAU), while the abscissa represents the retention time (minutes).

Figure 3 shows an MS spectral chart of a crude morpholino nucleic acid oligomer synthesized using a CE-G monomer. The ordinate represents the ion intensity (a.u.), while the abscissa represents the mass-charge ratio (m/z).

Figure 4 shows an MS spectral chart of a crude morpholino nucleic acid oligomer synthesized using a POB-G monomer. The ordinate represents the ion intensity (a.u.) and the abscissa represents the mass-charge ratio (m/z).

[Description of Embodiments]

[0019] The embodiments of the present invention are described below.

[0020] In the following production method, when a starting material has a substituent influencing the reaction (for example, hydroxy, amino, carboxy), the reaction is usually carried out after preliminary protection of the starting material with a suitable protecting group according to a known method. The protecting group can finally be cleaved according to any known method such as catalytic hydrogenation, alkali treatment, acid treatment.


Production method of the compound of the invention

[0021] The compound of the invention can be produced from a known compound or a readily producible intermediate for example by Production Method 1 to Production Method 3 shown below.

Production Method 1: When R³ is trialkylsilyloxy or diphenylalkylsilyloxy

[0022]

[C. 5]



wherein R² is defined as described above.

R⁷ represents trialkylsilyl or diphenylalkylsilyl.

R⁸ represents an arylsulfonyl which may be substituted with 1 to 3 alkyls.

R¹⁴ represents the group represented by the aforementioned Formula (2).

[0023] This reaction comprises a condensation reaction of Compound (6) with 2-cyanoethanol, and thus may be carried out according to a method known per se.


[0024] The amount of 2-cyanoethanol to be used is suitably within the range from 1 mole to 20 mole for 1 mole of Compound (6), preferably within the range from 1.2 mole to 10 mole for 1 mole of Compound (6). The usable solvent is not limited particularly as long as it is inert to the reaction, and can include, for example, acetonitrile, dichloromethane and N,N-dimethylformamide as well as mixtures thereof. Dichloromethane is especially preferred. The "base" which can be used in this step can include, for example, N-methylpyrrolidine and 1,8-diazabicyclo[5.4.0]undec-7-ene as well as mixtures thereof. The amount of the base to be used is suitably within the range from 1 mole to 20 mole for 1 mole of Compound (6), preferably within the range from 1 mole to 10 mole for 1 mole of Compound (6). The reaction temperature is suitably within the range from 0°C to 50°C. While the reaction time may vary depending on the kind of the starting material used, the reaction temperature, and is suitable within the range from 1 hour to 30 hours.

[0025] Compound (6) as a starting compound can be produced according to the method described in the section for preparing Compound 4 in Example 1 in WO2009/064471.

Production method 2: When R³ is hydroxyl

[0026]

[C. 6]



wherein R^2 , R^7 , and R^{14} are defined as described above.

[0027] This reaction comprises a reaction for cleaving R^7 on Compound (1A), and thus may be carried out according to a method known per se.

[0028] A "reagent for cleaving R^7 " which can be used in this step can include, for example, tetrabutylammonium fluoride, a salt of an amine with hydrofluoric acid or a mixture of an amine and hydrofluoric acid in a suitable ratio in a suitable solvent.


[0029] The usable solvent can include, for example, tetrahydrofuran (THF), acetonitrile, dichloromethane, toluene, dimethyl sulfoxide and N,N-dimethylformamide as well as solvent mixtures thereof. Especially, THF and dichloromethane are preferred.

[0030] While the amount of the reagent for cleaving R^7 which can be used in this step may vary depending on the kind of Compound (1A), the reagent for cleaving R^7 to be used, the solvent to be used, it is suitably within the range from 1 mole to 10 mole for 1 mole of Compound (1A), preferably within the range from 1.2 mole to 5 mole for 1 mole of Compound (A). The reaction temperature is suitably within the range from 0°C to 50°C. While the reaction time may vary depending on the kind of the starting material, the reaction temperature, it is suitably within the range from 1 hour to 30 hours.

Production method 3: When R^3 is a group represented by the following formula (5)

[0031]


[C. 7]



(5)

wherein X, Y, Z, and * are defined as described above.

[C. 8]



wherein R^2 , R^{14} , X, Y, and Z are defined as described above.

[0032] This reaction comprises a phosphoramidating reaction for Compound (1B), and thus may be carried out according to a method known per se.

[0033] The usable solvent is not limited particularly as long as it is inert to the reaction, and can include, for example, acetonitrile, dichloromethane and THF.

[0034] The amount of Compound (9) which can be used in this step is suitably within the range from 1 mole to 10 mole for 1 mole of Compound (1B), preferably within the range from 1.2 mole to 5 mole for 1 mole of Compound (1B).

[0035] The "activating agent" which can be used in this step can include, for example, 1H-tetrazole, 5-ethylthiotetrazole, 4,5-dichloroimidazole, 4,5-dicyanoimidazole, N-methylimidazole, 4-dimethylaminopyridine. N-Methylimidazole is especially preferred. The amount of the "activating agent" to be used is suitably within the range from 0.2 mole to 3 mole for 1 mole of Compound (9), preferably within the range from 0.5 mole to 2 mole for 1 mole Compound (9).


[0036] The "base" which can be used in this step may for example be N-ethylmorpholine. The amount of the base to be used is suitably within the range from 0.8 mole to 5 mole for 1 mole of Compound (9), preferably within the range from 1 mole to 3 mole for 1 mole of Compound (9). The reaction temperature is suitably within the range from 0°C to

80°C. While the reaction time may vary depending on the kind of the starting material, the reaction temperature, and is suitably in the range from 1 hour to 30 hours.

Production Method 4: When R¹ is hydrogen

[0037]

[C. 9]



wherein R², R³, and R¹⁴ are defined as described above.

[0038] This reaction comprises a reaction for deprotecting R¹⁴ of Compound (1D), and thus may be carried out according to a method known per se.

[0039] The "acid" which can be used in this step, i.e., the "reagent for cleaving R¹⁴" can include, for example, acetic acid, hydrochloric acid or phosphoric acid. The amount of the acid to be used is suitably within the range from 1 mole to 1000 mole for 1 mole of Compound (1D), preferably within the range from 10 mole to 100 mole for 1 mole of Compound (1D).


[0040] The solvent to be used is not limited particularly as long as it is inert to the reaction, and can include, for example, dichloromethane, methanol and water.

[0041] While the reaction time may vary depending on the kind of the starting material, the reaction temperature, it is suitably within the range from 0.5 hour to 5 hours.

Method for producing morpholino nucleic acid oligomer

[0042] A preferred morpholino nucleic acid oligomer is an oligomer having a group represented by the following formula as a building block.

[C 10]




wherein Base represents a nucleic acid base. X, and Y are defined as described above.

[0043] The morpholino nucleic acid oligomer may be produced, for example, according to the method described in WO1991/009033 or WO2009/064471. Especially, the morpholino nucleic acid oligomer can be produced according to the method described in WO2009/064471, or can be produced according to the method shown below.

[0044] As an embodiment of the morpholino nucleic acid oligomer, a compound represented by the following formula (I) (hereinafter referred to as Morpholino nucleic acid oligomer (I)) can be exemplified.

[C 11]



wherein Base, X, and Y are defined as described above; n is an integer within the range from 1 to 99, preferably is an integer within the range from 18 to 28.

[0045] Morpholino nucleic acid oligomer (I) may be produced according to a known method, and may be produced, for example, by carrying out the procedures of the steps described below.


[0046] The compounds and the reagents to be used in the steps described below are not limited particularly as long as they are used generally in producing the morpholino nucleic acid oligomers.

[0047] All of the steps described below can be carried out by liquid phase methods or solid phase methods (using manuals or commercially available solid phase automatic synthesizer). When a morpholino nucleic acid oligomer is produced by a solid phase method, then a method using an automatic synthesizer is desirable in view of simplification of operational procedures and accuracy of synthesis.

(1) Step A:

[0048] A step for producing a compound represented by the following formula (III) (hereinafter referred to as Compound (III)) by allowing an acid to act on a compound represented by the following formula (II) (hereinafter referred to as Compound (II)).

[C 12]



wherein n, X, and Y are defined as described above;

BP represents independently a nucleic acid base which may be protected;

R¹ represents a trityl group, monomethoxytrityl group or dimethoxytrityl group;

L represents hydrogen, acyl or a group represented by the following formula (IV) (hereinafter referred to as "Group (IV)").

[C 13]



(I V)

[0049] The "nucleic acid base" according to B^P can include, for example, a "nucleic acid base" similar to Base. Nevertheless, the amino group or the hydroxy group of the nucleic acid base according to B^P may be protected.

[0050] The protecting group for such an amino group is not limited particularly as long as it is used as a protecting group for a nucleic acid, and those exemplified typically can include benzoyl, 4-methoxybenzoyl, acetyl, propionyl, butyl, isobutyl, phenylacetyl, phenoxyacetyl, 4-tert-butylphenoxyacetyl, 4-isopropylphenoxyacetyl, (dimethylamino) methylene. The protecting group for a hydroxy group can include, for example, 2-cyanoethyl, 4-nitrophenethyl, phenylsulfonyl, methylsulfonyl, trimethylsilyl, phenyl which may be substituted in any substitutable positions by 1 to 5 electron-withdrawing groups, diphenylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl, methylphenylcarbamoyl, 1-pyrrolidinylcarbamoyl, morpholinocarbamoyl, 4-(tert-butylcarboxy)benzyl, 4-[(dimethylamino)carboxy]benzyl, 4-(phenylcarboxy)benzyl (for example, see WO2009/064471).

[0051] Among these, 2-cyanoethyl is preferred as a protecting group for the hydroxy group at 6-position of the guanine.

[0052] The "solid support" is not limited particularly as long as it can be used in a solid phase reaction of a nucleic acid, and desirably one which (i) is sparingly soluble in a reagent which can be used in the synthesis of morpholino nucleic acid derivatives (for example, dichloromethane, acetonitrile, tetrazole, N-methylimidazole, pyridine, acetic anhydride, lutidine, trifluoroacetic acid), (ii) is stable chemically to a reagent which can be used in the synthesis of morpholino nucleic acid derivatives, (iii) can be modified chemically, (iv) enables a desired loading of a morpholine nucleic acid derivative, (v) has a strength sufficient to tolerate a high pressure exerted during treatment, (vi) has a constant particle size range and distribution. Those exemplified typically can include swellable Polystyrene (for example, aminomethyl polystyrene resin 1% dibenzylbenzene crosslinking (200~400 mesh) (2.4~3.0mmol/g) (manufactured by Tokyo Chemical Industry Co., Ltd.), Aminomethylated Polystyrene Resin-HCl[dibenzylbenzene 1%, 100~200 mesh] (manufactured by Peptide Institute Inc.)), non-swellable polystyrene (for example, Primer Support (manufactured by GE Healthcare Ltd.)), PEG-chain binding type polystyrene (for example, NH₂-PEG resin (manufactured by Watanabe Chemical Industries, Ltd.), TentaGel resin), controlled pore glass (CPG) (for example, CPG's product), oxalylated controlled pore glass (for example, see, Nucleic Acids Research, Vol. 19, 1527 (1991) Alul et al.), TentaGel support-aminopolyethylene glycol derivatized support (for example, see, Tetrahedron Letters, Vol. 34, 3373 (1993) Wright et al.), Poros-polystyrene/divinylbenzene copolymer.

[0053] As a "linker", any known one used usually for linking nucleic acids or morpholino nucleic acid derivatives can be used, and can include 3-aminopropyl, succinyl, 2,2-diethanolsulfonyl and a long chain alkylamino (LCAA).

[0054] This step can be carried out by allowing an acid to act on Compound (II).

[0055] The "acid" which can be used in this step can include, for example, trifluoroacetic acid, dichloroacetic acid and trichloroacetic acid. The amount of the acid to be used is suitably within the range from 0.1 mole to 1000 mole for 1 mole of Compound (II), preferably within the range from 1 mole to 100 mole for 1 mole of Compound (II).

[0056] It is also possible to use an organic amine together with the aforementioned acid. The organic amine is not limited particularly and can include, for example, triethylamine. The amount of the organic amine to be used is suitably within the range from 0.01 mole to 10 mole for 1 mole of the acid, preferably within the range from 0.1 mole to 2 mole for 1 mole of the acid.

[0057] When using a salt or a mixture of an acid with an organic amine in this step, it can include a salt or a mixture of trifluoroacetic acid with triethylamine, more typically a mixture of 2 equivalents of trifluoroacetic acid with 1 equivalent of triethylamine.

[0058] The acid which can be used in this step can be used also as being diluted with a suitable solvent to a concentration within the range from 0.1 to 30%. The solvent is not limited particularly as long as it is inert to the reaction, and can include dichloromethane, acetonitrile, alcohols (ethanol, isopropanol, trifluoroethanol and the like), water or mixtures thereof.

[0059] The reaction temperature of the aforementioned reaction is, for example, preferably within the range from 10°C to 50°C, more preferably within the range from 20°C to 40°C, further preferably within the range from 25°C to 35°C.

[0060] While the reaction time may vary depending on the kind of the acid to be used and the reaction temperature, it is suitably within the range from 0.1 minute to 24 hours, preferably within the range from 1 minute to 5 hours.

[0061] Also after completion of this process, a base may be added if necessary to neutralize the acid remaining in the system. The "base" is not limited particularly and can include for example, diisopropylamine. The base may be used as being diluted with a suitable solvent to a concentration within the range from 0.1% (v/v) to 30% (v/v).


[0062] The solvent to be used in this step is not limited particularly as long as it is inert to the reaction, and can include dichloromethane, acetonitrile, alcohols (ethanol, isopropanol, trifluoroethanol and the like), water or mixtures thereof.

The reaction temperature is, for example, preferably within the range from 10°C to 50°C, more preferably within the range from 20°C to 40°C, further preferably within the range from 25°C to 35°C.

[0063] While the reaction time may vary depending on the kind of the base and the reaction temperature to be used, it is suitably within the range from 0.1 minute to 24 hours, preferably within the range from 1 minute to 5 hours.

[0064] A compound represented by the following formula (IIa) (hereinafter referred to as Compound (IIa)), wherein n is 1 and L is Group (IV) in Compound (II), can be produced according to the method shown below.

[C 14]




wherein B^P , R^1 , linker, and solid support are defined as described above.

Step 1:

[0065] A step for producing a compound represented by the following formula (VI) (hereinafter referred to as Compound (VI)) by allowing an acylating agent to act on a compound represented by the following formula (V).

[C 15]




wherein B^P , R^1 , and linker are defined as described above; R^6 represents a hydroxy group, halogen or amino.

[0066] This step can be carried out according to a known linker-introducing reaction using Compound (V) as a starting material.

[0067] Especially, a compound represented by the following formula (VIa) can be produced according to a method known as an esterification reaction using Compound (V) and succinic anhydride.

[C 16]




wherein B^P , and R^1 are defined as described above.

Step 2:

[0068] A step for producing Compound (IIa) by allowing a condensation agent to act on Compound (VI) and a solid support.

[C 17]




wherein B^P , R^6 , R^1 , linker, and solid support are defined as described above.

[0069] This step comprises a condensation reaction of Compound (VI) with a solid phase and thus may be carried out according to a method known as a condensation reaction.

[0070] A compound represented by the following formula (IIa2), wherein n is an integer within the range from 2 to 99 and L is Group (IV) in Compound (II), can be produced by using Compound (IIa) as a starting material, and by repeating the processes of Step A and Step B desired times according to the morpholino nucleic acid oligomer production method described in the present specification.


[C 18]



wherein B^P , X , Y , R^1 , linker, and solid support are defined as described above;
 n' represents an integer in the range from 1 to 98.

[0071] A compound represented by the following formula (IIb), wherein n is 1 and L is hydrogen in Compound (II), can be produced for example according to the method described in WO1991/009033.


[C 19]



wherein B^P , and R^1 are defined as described above.

[0072] A compound represented by the following formula (IIb2), wherein n is an integer within the range from 2 to 99 and L is hydrogen in Compound (II), can be produced by using Compound (IIb) as a starting material and by repeating the processes of Step A and Step B desired times according to the morpholino nucleic acid oligomer production method described in the present specification.


[C 20]



wherein B^P , n , R^1 , X , and Y are defined as described above.

[0073] A compound represented by the following formula (IIc), wherein $n=1$ and L is acyl in Compound (II), can be produced according to a method known as an acylation reaction to Compound (IIb).


[C 21]



wherein B^P , and R^1 are defined as described above;
 R^7 represents acyl.

[0074] A compound represented by the following formula (IIc2), wherein n is an integer within the range from 2 to 99 and L is acyl in Compound (II), can be produced using Compound (TTc) as a starting material and by repeating the processes of Step A and Step 3 desired times according to the morpholino nucleic acid oligomer Production method described in the present specification.

[C 22]




wherein B^P , n' , R^1 , R^7 , X, and Y are defined as described above.

(2) Step B:

[0075] A step for producing a compound represented by the following formula (VII) (hereinafter referred to as Compound (VII)) by allowing a morpholino monomer compound to act on Compound (III) in the presence of a base.

[C 23]




wherein B^P , L, n, P^1 , X, and Y are defined as described above.

[0076] This step can be carried out by allowing a morpholino monomer compound to act on Compound (III) in the presence of a base.

[0077] The morpholino monomer compound can include a compound represented by the following formula (VIII).

[C 24]



wherein B^P , R^1 , X, Y, and Z are defined as described above.

[0078] The "base" which can be used in this step can include diisopropylamine, triethylamine or N-ethylmorpholine. The amount of the base to be used is suitably within the range from 1 mole to 1000 mole for 1 mole of Compound (III), preferably within the range from 10 mole to 100 mole for 1 mole of Compound (III).

[0079] The morpholino monomer compound and the base which can be used in this step can be diluted with suitable solvent to concentrations within the range from 0.1% (v/v) to 30% (v/v). The solvent is not limited particularly as long as it is inert to the reaction, and can include N,N-dimethylimidazolidone, N-methylpiperidone, DMF, dichloromethane, acetonitrile, tetrahydrofuran or a mixture thereof.

[0080] The reaction temperature is, for example, preferably within the range from 0°C to 100°C, more preferably within the range from 10°C to 50°C.

[0081] While the reaction time may vary depending on the kind of the base to be used and the reaction temperature, it is suitably within the range from 1 minute to 48 hours, preferably within the range from 30 minutes to 24 hours.

[0082] Also after completion of this process, an acylating agent may be added if necessary. The "acylating agent" can include acetic anhydride, acetyl chloride, phenoxyacetic anhydride. The acylating agent may be diluted with a suitable solvent to a concentration within the range from 0.1% (v/v) to 30% (v/v). The solvent to be used in this step is not limited particularly as long as it is inert to the reaction, and can include dichloromethane, acetonitrile, alcohols (ethanol, isopropanol, trifluoroethanol and the like), water or mixtures thereof.


[0083] If necessary, it is possible to use, together with the acylating agent, a base such as pyridine, lutidine, collidine, triethylamine, diisopropylethylamine, N-ethylmorpholine. The amount of the acylating agent to be used is preferably within the range from 0.1 to 10000 mole equivalents, more preferably 1 to 1000 mole equivalents. The amount of the base to be used is suitably within the range from 0.1 mole to 100 mole for 1 mole of the acylating agent, preferably within the range from 2 mole to 10 mole for 1 mole of the acylating agent.

[0084] The reaction temperature of this reaction is preferably within the range from 10°C to 50°C, more preferably within the range from 10°C to 50°C, more preferably within the range from 20°C to 40°C, further preferably within the range from 25°C to 35°C. While the reaction time may vary depending on the kind of the acylating agent to be used and the reaction temperature, it is suitably within the range from 0.1 minute to 24 hours, preferably within the range from 1 minute to 5 hours.

(3) Step C:

[0085] A step for producing a compound represented by the formula (IX) by allowing a deprotecting agent to act on Compound (VII) produced in Step B, in order to detach the protecting group.

[C 25]



15 wherein Base, B^P, L, n, R¹, X, and Y are defined as described above.

[0086] This step can be carried out by allowing a deprotecting agent to act on Compound (VII).


[0087] The "deprotecting agent" can include a concentrated aqueous ammonium solution and methylamine. The "deprotecting agent" which can be used in this step may be diluted for example with water, methanol, ethanol, isopropyl alcohol, acetonitrile, tetrahydrofuran, DMF, N,N-dimethylimidazolidone, N-methylpiperidone or a mixture thereof. Among those, ethanol is preferred. The amount of the deprotecting agent to be used is, for example, suitably within the range from 1 mole to 100000 mole for 1 mole of Compound (VII), preferably within the range from 10 mole to 1000 mole for 1 mole of Compound (VII).

[0088] The reaction temperature is, for example, suitably within the range from 15°C to 75°C, preferably within the range from 40°C to 70°C, more preferably within the range from 50°C to 60°C. While the deprotecting reaction time may vary depending on the kind of Compound (VII), the reaction temperature, it is suitably within the range from 10 minutes to 30 hours, preferably within the range from 30 minutes to 24 hours, more preferably within the range from 5 hours to 20 hours.

(4) Step D:

[0089] A step for producing a morpholino nucleic acid oligomer (I) by allowing an acid to act on Compound (IX) produced in Step C.

[C 26]



wherein Base, n, R¹, X, and Y are defined as described above.

[0090] This step can be carried out by adding an acid to Compound (IX).

[0091] The "acid" which can be used in this step can include, for example, trichloroacetic acid, dichloroacetic acid, acetic acid, phosphoric acid and hydrochloric acid. The amount of the acid to be used is adjusted suitably to allow the pH of the solution to be within the range from 0.1 to 4.0, more preferably 1.0 to 3.0. The solvent is not limited particularly as long as it is inert to the reaction, and can include acetonitrile, water or solvent mixtures thereof.

[0092] The reaction temperature is preferably within the range from 10°C to 50°C, more preferably within the range from 20°C to 40°C, further preferably within the range from 25°C to 35°C. The deprotecting reaction time may vary depending on the kind of Compound (IX), the reaction temperature, and is suitably within the range from 0.1 minute to 5 hours, preferably within the range from 1 minute to 1 hour, more preferably within the range from 1 minute to 30 minutes.

[0093] The morpholino nucleic acid oligomer (I) can be obtained from the reaction mixture obtained in this step by

using an ordinary separation and isolation means, such as extraction, concentration, neutralization, filtration, centrifugation, recrystallization, reverse phase column chromatography on C₈ to C₁₈, cation exchange chromatography, anion exchange chromatography, gel filtration column chromatography, high pressure liquid chromatography, dialysis, ultrafiltration, which can be carried out alone or in combination, thereby a desired morpholino nucleic acid oligomer (I) is isolated and purified (for example, see WO1991/09033).

[0094] When using a reverse phase chromatography to purify the morpholino nucleic acid oligomer (I), the elution solvent can include a solution mixture of a 20mM triethylamine/acetic acid buffer solution and acetonitrile.

[0095] When using an ion exchange chromatography to purify the morpholino nucleic acid oligomer (I), for example, a solution mixture of a 1M saline and a 10 mM aqueous solution of sodium hydroxide may be used.

[0096] Although the compound of the invention can be used directly as a starting monomer for synthesis of a morpholino nucleic acid oligomer or a starting material for synthesizing such a starting monomer, it can be used in the form of a salt by means of a known method. For example, such a salt may be a salt of a mineral acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, and a salt of an organic acid such as acetic acid, citric acid, tartaric acid, maleic acid, succinic acid, fumaric acid, p-toluenesulfonic acid, benzenesulfonic acid, methanesulfonic acid.

[0097] Among the compound of the invention or a salt thereof, one having asymmetric carbon atoms may exist, and respective optical isomers and mixtures thereof are encompassed also by the present invention. The optical isomers can be obtained via optical resolution by a known method using an optically active acid (tartaric acid, dibenzoyltartaric acid, mandelic acid, 10-camphorsulfonic acid and the like) from a racemic form obtained as described above while utilizing the basicity thereof, or can be produced by using a preliminarily prepared optically active compound as a starting material. Otherwise, an optical resolution using a chiral column or an asymmetric synthesis can be used for the production.

[0098] Also when geometric isomers or tautomeric isomers of the compound of the invention or a salt thereof exist, the present invention encompasses not only a single isomer thereof but also a mixture thereof.

[0099] The compound of the invention or a salt thereof thus produced, can be separated and purified by a technique known per se such as concentration, liquid nature conversion, migration to solvent, solvent extraction, crystallization, recrystallization, fractional distillation, and chromatography.

[EXAMPLES]

[0100] Hereinafter, the present invention will be described in more detail with reference to REFERENCE EXAMPLES, EXAMPLES, PRODUCTION EXAMPLES and TEST EXAMPLES below, but is not deemed to be limited thereto.

[REFERENCE EXAMPLE 1]

N⁹-{(2R,6S)-6-(Hydroxymethyl)morpholin-2-yl}-N²-(phenoxyacetyl)guanine p-toluenesulfonate

Step 1: Production of N²-(phenoxyacetyl)guanosine

[0101] Guanosine, 100 g, was dried at 80°C under reduced pressure for 24 hours. After 500 mL of pyridine (anhydrous) and 500 mL of dichloromethane (anhydrous) were added thereto, 401 mL of chlorotrimethylsilane was dropwise added to the mixture under an argon atmosphere at 0°C, followed by stirring at room temperature for 3 hours. The mixture was again ice-cooled and 66.3 g of phenoxyacetyl chloride was dropwise added thereto. Under ice cooling, the mixture was stirred for further 3 hours. To the reaction solution was added 500 mL of methanol, and the mixture was stirred at room temperature overnight. The solvent was then removed by distillation under reduced pressure. To the residue was added 500 mL of methanol, and concentration under reduced pressure was performed 3 times. To the residue was added 4L of water, and the mixture was stirred for an hour under ice cooling. The precipitates formed were taken out by filtration, washed sequentially with water and cold methanol and then dried to give 150.2 g of the objective compound (cf. : Org. Lett. (2004), Vol. 6, No. 15, 2555-2557).

Step 2:

N⁹-{(2R,6S)-5-(Hydroxymethyl)morpholin-2-yl}-N²-(phenoxyacetyl)guanine p-toluenesulfonate

[0102] In 480 mL of methanol was suspended 30 g of the compound obtained in Step 1, and 130 mL of 2N hydrochloric acid was added to the suspension under ice cooling. Subsequently, 56.8 g of ammonium tetraborate tetrahydrate and 16.2 g of sodium periodate were added to the mixture in the order mentioned and the mixture was stirred at room temperature for 3 hours. The reaction solution was ice cooled and the insoluble matters were removed by filtration, followed by washing with 100 mL of methanol. The filtrate and washing liquid were combined and the mixture was ice cooled. To the mixture was added 11.52 g of 2-picoline borane. After stirring for 20 minutes, 54.6 g of p-toluenesulfonic

acid monohydrate was slowly added to the mixture, followed by stirring at 4°C overnight. The precipitates were taken out by filtration and washed with 500 mL of cold methanol and dried to give 17.7 g of the objective compound (yield: 43.3%).
¹H NMR (DMSO-d₆): δ 9.9-9.2 (2H, br), 8.35 (1H, s), 7.55 (2H, m), 7.35 (2H, m), 7.10 (2H, d, J=7.82Hz), 7.00 (3H, m), 5.95 (1H, dd, J=10.64, 2.42Hz), 4.85 (2H, s), 4.00 (1H, m), 3.90-3.60 (2H, m), 3.50-3.20 (5H, m), 2.90 (1H, m), 2.25 (3H, s)

[REFERENCE EXAMPLE 2]

Production of 4-[[[(2S,6R)-6-(4-benzamido-2-oxopyrimidin-1-yl)-4-tritylmorpholin-2-yl]methoxy]-4-oxobutanoic acid loaded onto aminomethylpolystyrene resin (manufactured by GE Healthcare, Custom Primer Support Amino 200, 28-9229-46)

[0103] Under argon atmosphere, 0.46 g of *N*-{1-[(2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]-2-oxo-1,2-dihydropyrimidin-4-yl}benzamide and 0.15 g of 4-dimethylaminopyridine (4-DMAP) were suspended in 10 mL of dichloromethane, and 0.12 g of succinic anhydride was added to the suspension, followed by stirring at room temperature for 3 hours. To the reaction solution was added 1 mL of methanol, and the mixture was concentrated under reduced pressure. The residue was extracted using ethyl acetate and 0.5M aqueous potassium dihydrogenphosphate solution. The resulting organic layer was washed sequentially with 0.5M aqueous potassium dihydrogenphosphate solution, water and brine in the order mentioned. The resulting organic layer was dried over sodium sulfate and concentrated under reduced pressure.

[0104] After the obtained residue was dissolved in 50 mL of pyridine (dehydrated), 0.1 g of 4-DMAP and 1.5 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride were added to the solution. Then, 5.0 g of Aminomethyl Polystyrene Resin (manufactured by GE Healthcare, Custom Primer Support Amino 200, 28-9229-46) and 1.7 mL of triethylamine were added to the mixture, followed by shaking at room temperature for 6 days. After completion of the reaction, the resin was taken out by filtration. The resulting resin was washed sequentially with pyridine, methanol and dichloromethane in the order mentioned, and dried under reduced pressure. To the resulting resin were added 40 mL of tetrahydrofuran (dehydrate), 3 mL of acetic anhydride and 3 mL of 2,6-lutidine, and the mixture was shaken at room temperature for 1.5 hours. The resin was taken out by filtration, washed sequentially with pyridine, methanol and dichloromethane in the order mentioned, and dried under reduced pressure to give 5.0 g of the product.

[0105] The loading amount of the product was determined the molar amount of the trityl per one g resin by measuring UV absorbance at 409 nm using a known method. The loading amount of the resin was 46.3 μmol/g.

Conditions of UV measurement

[0106]

Device: U-2910 (Hitachi, Ltd.)
 Solvent: methanesulfonic acid
 Wavelength: 265 nm
 ε Value: 45000

[REFERENCE EXAMPLE 3]

Production of 4-[[[(2S, 6R)-6-(4-benzamido-2-oxopyrimidin-1-yl)-4-tritylmorpholin-2-yl]methoxy]-4-oxobutanoic acid loaded onto Aminomethyl Polystyrene Resin cross-linked with 1% DVB (manufactured by Tokyo Chemical Industry Co., Ltd., A1543)

[0107] Under argon atmosphere, 30 g of *N*-{1-[(2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]-2-oxo-1,2-dihydropyrimidin-4-yl}benzamide and 9.6 g of 4-dimethylaminopyridine (4-DMAP) were suspended in 60 mL of dimethylformamide, and 7.86 g of succinic anhydride was added to the suspension, followed by stirring at room temperature for 2 hours. To the reaction solution was added 1M aqueous potassium dihydrogenphosphate solution, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed sequentially with 1M aqueous potassium dihydrogenphosphate solution, water and brine in the order mentioned. The resulting organic layer was dried over magnesium sulfate and concentrated under reduced pressure to give 34.0 g as crude crystal.

[0108] After 29.5 g of crude crystal was dissolved in 300 mL of pyridine (dehydrated), 5.1 g of 4-DMAP and 20.1 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride were added to the solution. Then, 25.0 g of Aminomethyl Polystyrene Resin cross-linked with 1% DVB (manufactured by Tokyo Chemical Industry Co., Ltd., A1543) and 24 mL of triethylamine were added to the mixture, followed by shaking at room temperature for 3 days. After completion of the reaction, the resin was taken out by filtration. The resulting resin was washed sequentially with pyridine, methanol and

dichloromethane in the order mentioned, and dried under reduced pressure. To the obtained resin were added 300 mL of tetrahydrofuran (dehydrate), 30 mL of acetic anhydride and 30 mL of 2,6-lutidine, and the mixture was shaken at room temperature for 2.5 hours. The resin was taken out by filtration, washed sequentially with pyridine, methanol and dichloromethane in the order mentioned, and dried under reduced pressure to give 33.2 g of the product.

[0109] The loading amount of the product was determined the molar amount of the trityl per one g resin by measuring UV absorbance at 409 nm using a known method. The loading amount of the resin was 292.4 $\mu\text{mol/g}$.

Conditions of UV measurement

[0110]

Device: U-2910 (Hitachi, Ltd.)

Solvent: methanesulfonic acid

Wavelength: 265 nm

ϵ Value: 45000

[Example 1]

[(2S, 6R)-6-{N²-(phenoxyacetyl)-O⁶-(2-cyanoethyl)guanin-9-yl}-4-tritylmorpholin-2-yl]methyl dimethylphosphoramidate

Step 1:

Production of N⁹-[(2R,6S)-6-hydroxymethyl-4-tritylmorpholin-2-yl]-N²-(phenoxyacetyl)guanine

[0111] In 30 mL of dichloromethane was suspended 2.0 g of N⁹-[(2R,6S)-6-(hydroxymethyl)morpholin-2-yl]-N²-(phenoxyacetyl)guanine p-toluenesulfonate (REFERENCE EXAMPLE 1), and 13.9 g of triethylamine and 18.3 g of trityl chloride were added to the suspension under ice cooling. The mixture was stirred at room temperature for an hour. The reaction solution was washed with saturated sodium bicarbonate aqueous solution and then with water, and dried over sodium sulfate. The organic layer was concentrated under reduced pressure. To the residue was added 40 mL of 0.2M sodium citrate buffer (pH 3)/methanol (1:4 (v/v)), and the mixture was stirred. Subsequently, 40 mL of water was added and the suspension mixture was stirred for an hour under ice cooling. The precipitates were taken out by filtration, washed with cold methanol and dried to give 1.84 g of the objective compound (yield: 82.0%).

Step 2:

Production of N⁹-[(2R, 6S)-5-[(tert-butyldimethylsilyloxy)methyl]-4-tritylmorpholin-2-yl]-N²-(phenoxyacetyl)guanine

[0112] In 300 mL of dichloromethane was dissolved 38.3 g of the compound obtained by Step 1, and 4.64 g of imidazole and 9.47 g of t-butyldimethylsilyl chloride were added to the solution in the order mentioned under ice cooling. The reaction solution was stirred at room temperature for an hour. The reaction solution was washed with 0.2M sodium citrate buffer (pH 3) and then with brine, and dried over magnesium sulfate. The organic layer was concentrated under reduced pressure to give 44.1 g of the objective compound as a crude product.

Step 3:

Production of N⁹-[(2R,6S)-6-[(tert-butyldimethylsilyloxy)methyl]-4-tritylmorpholin-2-yl]-N²-(phenoxyacetyl)-O⁶-triisopropylbenzene sulfonyl guanine

[0113] In 300 mL of dichloromethane was dissolved 44.1 g of the compound obtained by Step 2, and 0.64 g of 4-dimethylaminopyridine, 29.2 mL of triethylamine and 19.0 g of triisopropylbenzenesulfonyl chloride were added to the solution under ice cooling. The reaction solution was stirred at room temperature for an hour. The reaction solution was washed with 1M aqueous sodium dihydrogenphosphate solution, and dried over sodium sulfate. The organic layer was concentrated under reduced pressure to give 60.5 g of the objective compound as a crude product.

Step 4:

Production of N⁹-[(2R,6S)-6-((tert-butyldimethylsilyloxy)methyl)-4-tritylmorpholin-2-yl]-N²-(phenoxyacetyl)-O⁶-(2-cyanoethyl)guanine

[0114] In 300 mL of dichloromethane was dissolved 60.5 g of the compound obtained by Step 3, and 54.5 mL of N-methylpyrrolidine was added to the solution under ice cooling. The reaction solution was stirred under ice cooling for an hour. Then, 37.2 g of ethylene cyanohydrins, and 11.96 g of 1,8-diazabicyclo [5.4.0] undec-7-ene were added to the solution, the solution was stirred under ice cooling for 2 hours. The reaction solution was washed with 1M aqueous sodium dihydrogenphosphate solution and then with water, and dried over sodium sulfate. The organic layer was concentrated under reduced pressure to give 72.4 g of the objective compound as a crude product.

Step 5:

Production of N⁹-[(2R,6S)-6-hydroxymethyl-4-tritylmorpholin-2-yl]-N²-(phenoxyacetyl)-O⁶-(2-cyanoethyl)guanine

[0115] In 300 mL of dichloromethane was dissolved 72.4 g of the compound obtained by Step 4, and 21.1 g of triethylamine trihydrofluoride was added to the solution. The reaction solution was stirred at room temperature, for 17 hours. The reaction solution was poured into cold saturated sodium bicarbonate aqueous solution to neutralize the reaction solution, and then the dichloromethane layer was dried over sodium sulfate. The organic layer was concentrated under reduced pressure. The residue was purified by a silica gel column chromatography (PSQ100B (manufactured by FUJI SILESIA CHEMICAL LTD. The same shall apply hereinafter.)) to give 14.3 g of the objective compound (yield from Step 2: 39.2%).

Step 6:

Production of [(2S, 6R)-6-{N²-(phenoxyacetyl)-O⁶-(2-cyanoethyl)guanin-9-yl}-4-tritylmorpholin-2-yl]methyl dimethylphosphoramidochloridate

[0116] Under argon atmosphere, 4.03 mL of dimethylaminophosphoryl dichloride was added to 86 mL of THF, and 3.37 mL of N-methylimidazole was added to the reaction solution. The solution was changed into a suspension. Five minutes later, to the suspension was added 11.86 g of the powdered compound obtained by Step 5. The reaction mixture was stirred for 5 minutes. Then, 2.16 mL of N-ethylmorpholine was added to the mixture, the solution was stirred at room temperature for 3 hours.

[0117] The reaction solution was poured into ice-cooled 1M sodium dihydrogenphosphate aqueous solution, and was extracted with 300 mL of ethyl acetate. The organic layer was washed with brine and dried over sodium sulfate. The organic layer was concentrated under reduced pressure. The residue was purified by a silica gel column chromatography (PSQ100B) to give 9.9 g of the objective compound (yield: 70.7%).

¹H-NMR (CDCl₃): δ 8.85 (1H, bs), 7.85 (1H, d, J=3.45Hz), 7.60-7.00(20H,m), 6.30 (1H, d, J=9.51Hz), 4.90-4.70 (4H, m), 4.60-4.40 (1H, m), 4.20-4.00 (1H, m), 3.50 (1H, d, J=11.28Hz), 3.25 (1H, d, J=10.21Hz), 3.00 (2H, t, J=6.56Hz), 2.65 (6H, dd, J=13.89, 4.1Hz), 1.85-1.55 (2H, m)

³¹P-NMR (CDCl₃): δ 20.7097, 20.3500

[0118] The Table 1 shows the chemical structures and the abbreviation of the morpholino monomer compound used in the following PRODUCTION EXAMPLES and TEST EXAMPLES.

[Table 1]


Chemical structure			
Abbreviation	A ^P	C ^P	T ^P
Chemical structure			
Abbreviation	C E - G	P O B - G	

Production Example 1

Synthesis of morpholine nucleic acid oligomer having the following structure and base sequence 5'-CAGTGC-3' using CE-G

[0119]

[C 27]



[Step 1]

[0120] 216 mg (10 μ mol) of 4-[[[(2S,6R)-6-(4-benzamide-2-oxypyrimidin-1-yl)-4-tritylmorpholin-2-yl]methoxy]-4-oxobutanoic acid supported on an aminomethylpolystyrene resin (Reference Example 2) was transferred into a column for synthesis, which was loaded in an automatic synthesizing machine (Oligopilot 10: manufactured by GE healthcare). Other required reagents were prepared and also loaded. The solid phase synthesis was performed at 50°C (using a column oven) under the condition shown in Table 2.

[Table 2]Step	Process	Solution	Time (min.)
1	Deblocking	Deblocking solution	2.0
2	Washing	Acetonitrile	1.0

(continued)

[Table 2]Step	Process	Solution	Time (min.)
3	Coupling	Morpholino monomer solution (7 eq.) + Activator solution (*)	90
4	washing	Acetonitrile	1.0
*The monomer solution and the activator solution were set at a volume ratio of 6:4.			

[0121] As a deblocking solution, a dichloromethane solution containing 3% (w/v) trichloroacetic acid was used. As an activator, acetonitrile, solution containing 20% (v/v) N,N-diisopropylethylamine and 10% (v/v) tetrahydrofuran was used. As morpholino monomer compounds, A^P, C^P, T^P and CE-G shown in Table 1 were used.

[0122] As a morpholino monomer solution, the aforementioned morpholino monomer compound dissolved at 0.13 to 0.15M in tetrahydrofuran was used (A^P, C^P: 0.14M; T^P: 0.15M; CE-G: 0.13M).

[Step 2]

[0123] The morpholine nucleic acid oligomer supported on the aminomethylpolystyrene resin obtained in Step 1 was taken out of the reaction vessel, and dried under reduced pressure at room temperature for 2 hours or longer. 10 mg of the morpholino nucleic acid oligomer supported on the aminomethylpolystyrene resin thus dried was placed in the reaction vessel, to which 1 mL of 28% aqueous ammonia/ethanol (1/3) was added and stirred for 15 hours at 55°C. The aminomethylpolystyrene resin was filtered and washed with 1.0 mL of ethanol. The filtrate obtained was combined with 10 mL of ethyl ether. After centrifugation, the supernatant was discarded, and then after drying under reduced pressure, the intended substance was obtained as a white precipitate.

MALDI-TOF-MS: Calculated: 1921.66

Found: 1917.69

Production Example 2

Synthesis of morpholino nucleic acid oligomer having base sequence 5'-CAGTGC-3' using POB-G

[0124] Instead of CE-G monomer, [(2S, 6R)-6-{N'-(phenoxyacetyl)-O⁶-(pivaloyloxybenzyl)guanidin-9-yl}-4-tritylmorpholin-2-yl]methyl dimethylphosphoroamide chlorinate (see, WO2009/064471 A1, hereinafter referred to as POG-G (see Table 1)) was used, and the morpholino nucleic acid oligomer having the sequence similar to that in Production Example 1 was produced by the methods similar to that in Step 1 and Step 2 in Production Example 1.

Production Example 3 Synthesis of morpholino nucleic acid oligomer having base sequence 5'-CCTCCGGTCTGAAG-GTGT-3'

[0125] 6.02 g (1.75 mmol) of 4-[(2S,6R)-6-(4-benzamide-2-oxypyrimidin-1-yl)-4-tritylmorpholin-2-yl]methoxy-4-oxobutanoic acid supported on an aminomethylpolystyrene resin (Reference Example 3) was transferred into a reaction vessel, the vessel was added with 90 mL of dichloromethane, and allowed to stand for 30 minutes. After filtration, the synthetic cycle shown in Table 3 was started. In order to obtain the compound having the designated base sequence, the morpholino monomer compounds in the respective cycles were added as appropriate.

[Table 3]Step	Reagent	Volume (mL)	Time (min)
1	deblocking solution	90	5.0
2	deblocking solution	90	5.0
3	deblocking solution	90	5.0
4	deblocking solution	90	2.0
5	deblocking solution	90	5.0
6	deblocking solution	90	5.0
7	neutralizing solution	90	1.5

(continued)

[Table 3]Step	Reagent	Volume (mL)	Time (min)
8	neutralizing solution	90	1.5
9	neutralizing solution	90	1.5
10	neutralizing solution	90	1.5
11	neutralizing solution	90	1.5
12	neutralizing Solution	90	1.5
13	dichloromethane	90	0.5
14	dichloromethane,	90	0.5
15	dichloromethane,	90	0.5
16	coupling solution B	60	0.5
17	coupling solution A	20 - 35 *1	90 - 300 *2
18	dichloromethane	90	0.5
19	dichloromethane	90	0.5
20	dichloromethane,	90	0.5
21	capping solution	90	3.0
22	capping solution	90	3.0
23	dichloromethane	90	0.5
24	dichloromethane	90	0.5
25	dichloromethane	90	0.5
*1 Minimum amount required for allowing solid support to be swollen to enable stirring. *2 90 minutes for 10-mer or under, 300 minutes for 11 to 21 mer			

[0126] As a deblocking solution, a mixture of trifluoroacetic acid (2 equivalents) and triethylamine (1 equivalent) dissolved at 3% (w/v) in a dichloromethane, solution containing 1% (v/v) ethanol and 10% (v/v) 2, 2, 2-trifluoroethanol was used. As a neutralizing solution, N,N-diisopropylethylamine dissolved at 5% (v/v) in a dichloromethane solution containing 25% (v/v) 2-propanol was used.

[0127] As Coupling Solution A, a morpholino monomer compound (A^P, C^P, T^P and CE-G) dissolved at 0.15M in 1,3-dimethyl-2-imidazolidinone solution containing 10% (v/v) N,N-diisopropylethylamine was used. As Coupling Solution B, N,N-diisopropylethylamine dissolved at 10% (v/v) in 1,3-dimethyl-2-imidazolidinone was used. As Capping Solution, dichloromethane containing 20% (v/v) acetic anhydride and 30% (v/v) 2,6-lutidine dissolved therein was used.

[0128] The morpholino nucleic acid oligomer supported on the aminomethylpolystyrene resin synthesized as described above was recovered from the reaction vessel, dried under reduced pressure at room temperature for 2 hours or longer. The morpholino nucleic acid oligomer supported on the aminomethylpolystyrene resin thus dried was placed in the reaction vessel, to which 350 mL of 28% aqueous ammonia/ethanol (1/4) was added and stirred for 15 hours at 55°C. The aminomethylpolystyrene resin was filtered and washed with 150 mL of water%ethanol (1/4). The filtrate obtained was concentrated under reduced pressure. The residue obtained was dissolved in 400 ml of solution mixture of 20mM acetic acid-triethylamine buffer (TEAA buffer) and acetonitrile (4/1) and filtered through a membrane filter. The filtrate obtained was purified by a reverse phase HPLC. The conditions used are shown in Table 4.

[Table 4]

Column	XTerra MS18 (Waters, φ50x 100 mm, 1CV = 200 mL)
Flow rate	60 mL/min
Column temperature	room temperature
Solution A	20 mM TEAA buffer
Solution B	CH ₃ CN

(continued)

Column	XTerra MS18 (Waters, ϕ 50x 100 mm, 1CV = 200 mL)
Gradient	(B) conc. 20→50% /9CV

[0129] Each fraction was analyzed and the intended substance was recovered and concentrated under reduced pressure to obtain a pale yellow solid. The solid obtained was suspended in 200 mL of a 10mM aqueous solution of phosphoric acid. The suspension was added with 10 mL of a 2M aqueous solution of phosphoric acid and stirred for 15 minutes. Then, 15 mL of a 2M aqueous solution of sodium hydroxide was also added for neutralization. And then, 20 mL of the 2M aqueous solution of sodium hydroxide was further added to basify the solution. The mixture was then filtered through a membrane filter (0.22 μ m) and rinsed with 180 mL of a 10 mM aqueous solution of sodium hydroxide to give an aqueous solution (400 mL) containing the intended substance (5.8 g, yield: 50%) was obtained.

EST-TOF-MS Calculated: 6609.62

Found: 6609.09

Test Example 1

Comparison of morpholino nucleic acid oligomer produced using the compound of the invention (CE-G) (Production Example 1) and morpholino nucleic acid oligomer produced using prior art compound (POB-G) (Production Example 2)

(1) Comparison of purity or yield of synthesized morpholino nucleic acid oligomers

[0130] Each of the morpholino nucleic acid oligomers supported on the aminomethylpolystyrene resins obtained by the procedures similar to Step 1 in Production Example 1 and Step 1 in Production Example 2 was treated with a concentrated aqueous ammonia/ethanol mixture solution and the morpholino nucleic acid oligomers were cleaved from the solid phase supports. After removing the solid support by filtration, the filtrate was added with a large excess of ether and subjected to centrifugation, and the supernatant was discarded to recover the crude product of the relevant oligomer as a solid. The solid was dried and then dissolved in water (20 mL), 5 μ l of which was taken and subjected to HPLC to measure the designated morpholino nucleic acid oligomer content in the relevant crude mixture. The results are shown in HPLC chromatograms respectively in Figure 1 and Figure 2.

[0131] The measurement conditions are shown below.

Measurement conditions:

[0132]

HPLC Instrument

Pumping unit: LC-10AT VP (produced by Shimadzu Corporation)

Detector: SPD-10AVP (produced Shimadzu Corporation) Reverse phase HPLC column

XBridge [2.5 μ m, ϕ 4.6 mm x 50 mm] (produced by Waters)

Column temperature: 60°C

Mobile phase

Gradient: Linear gradient 20 minutes (Solution B: 0 to 40%)

Solution A: 50mM triethylamine - Acetic acid buffer solution

Solution B: Acetonitrile

Mobile phase flow rate: 0.75 ml/min

UV/Visible spectrophotometer detection wavelength: 260nm

[0133] The area percent (%) and the peak area (μ AU·sec) of the designated morpholino nucleic acid oligomer contained in the crude mixture obtained by analyzing the HPLC chromatograms in Figure 1 and Figure 2 are shown in Table 5.

[Table 5]

	Type of G-monomer	Area percent (%)	Peak area (μ AU·sec)
PRODUCTION EXAMPLE 1	CE-G	67.0	6868358
PRODUCTION EXAMPLE 2	POB-G	47.8	5364747

[0134] The results shown in Table 5 indicate that the area percent is higher and the peak area is larger when using the CE-G monomer in the synthesis of the morpholino nucleic acid oligomers than when using the POB-G monomer. The morpholino nucleic acid oligomer synthesized using the compound of the invention has a higher purity and yield. It is clear that the present invention is superior to the prior art.

(2) Comparison of synthesized morpholine nucleic acid oligomer by MS analysis

[0135] The respective crude morpholino nucleic acid oligomers obtained in Section (1) described above were examined for the mass spectra (MALDI-TOF-MS; produced by Autoflex; Bruker Daltonics) to obtain the mass spectrum shown respectively in Figure 3 and Figure 4.


[0136] As a result, it was revealed that when using the POB-G monomer (Figure 4) there observed a by-product which was not observed when using the CE-G monomer (Figure 3). The measured value of the molecular weight of this by-product was greater by 106 than the standard peak of the designated morpholino nucleic acid oligomer, suggesting the presence of a p-hydroxybenzyl adduct which was reported in WO2009/064471.

[0137] On the other hand, when using the CE-G monomer, the acrylonitrile adduct was not found in spite of the β -cleavage of the CE group (Figure 3), indicating that the CE-G monomer performs excellently in the synthesis of the morpholino nucleic acid oligomer.

Claims


1. A compound represented by the following general formula (1) or a salt thereof:

[C.1]



wherein R^1 represents hydrogen or a group represented by the following general formula (2):

[C.2]




(wherein * represents the binding position;


R¹¹, R¹², R¹³ are the same or different and each represents hydrogen, alkyl or alkoxy)

R² represents a group represented by the following general formula (3) or (4):

[C.3]



(3)



(4)


(wherein * is defined as described above;

R⁴ represents alkyl, arylmethyl or aryloxymethyl;

R⁵, R⁶ are the same or different and each represents alkyl)

R³ represents a hydroxy group which may be protected by trialkylsilyl or diphenylalkylsilyl, or a group represented by the following general formula (5):

[C.4]



(5)

(wherein * is defined as described above;

X represents O or S;

Y represents dialkylamino or alkoxy;

Z represents halogen).

2. The compound or a salt thereof according to claim 1, wherein X is O, Y is dialkylamino, and Z is chlorine.
3. The compound or a salt thereof according to claim 1, wherein R³ is a hydroxy group which may be protected by t-butyltrimethylsilyl or t-butyltriphenylsilyl.
4. The compound or a salt thereof according to claim 1, wherein R⁴ is phenoxyethyl.
5. The compound or a salt thereof according to claim 1, wherein R¹ is trityl, 4-methoxytrityl, 4-methyltrityl, 4,4'-dimethyltrityl, 4,4'-dimethoxytrityl, or 4,4',4''-trimethyltrityl.
6. A compound selected from the following (1) to (3), or a salt thereof:

(1) N⁹-[(2R,6S)-6-[(tert-butyltrimethylsilyloxy)methyl]-4-tritylmorpholin-2-yl]-N²-(phenoxyacetyl)-O⁶-(2-cyanoethyl)guanine,


(2) N⁹-[(2R,6S)-6-hydroxymethyl-4-tritylmorpholin-2-yl]-N²-(phenoxyacetyl)-O⁶-(2-cyanoethyl)guanine,

(3) [(2S,6R)-6-{N²-(phenoxyacetyl)-O⁶-(2-cyanoethyl)guanine-9-yl}-4-tritylmorpholin-2-yl]methyl dimethylphosphoroamidochloridate.

Patentansprüche

1. Verbindung, die durch die folgende allgemeine Formel (1) dargestellt ist, oder ein Salz davon:


[C.1]



(1)

wobei R¹ Wasserstoff oder eine Gruppe darstellt, die durch die folgende allgemeine Formel (2) dargestellt ist:

[C.2]




(2)

(wobei* die Position der Bindung darstellt;


R¹¹, R¹², R¹³ gleich oder verschieden sind und jedes Wasserstoff, Alkyl oder Alkoxy ist)

R² eine Gruppe darstellt, die durch die folgende allgemeine Formel (3) oder (4) dargestellt ist:

[C.3]



(3)



(4)


(wobei * wie oben definiert ist;

R⁴ Alkyl, Arylmethyl oder Aryloxymethyl darstellt;

R⁵, R⁶ gleich oder verschieden sind und jedes Alkyl darstellt)

R³ eine Hydroxy-Gruppe darstellt, die durch Trialkylsilyl oder Diphenylalkylsilyl geschützt sein kann, oder eine Gruppe, die durch die folgende allgemeine Formel (5) dargestellt ist:

[C.4]



(5)

(wobei * wie oben definiert ist;
X O oder S darstellt;
Y Dialkylamino oder Alkoxy darstellt;
Z Halogen darstellt).


2. Verbindung oder Salz davon nach Anspruch 1, wobei X O ist, Y Dialkylamino ist und Z Chlor ist.
3. Verbindung oder Salz davon nach Anspruch 1, wobei R³ eine Hydroxy-Gruppe ist, die durch t-Butyldimethylsilyl oder t-Butyldiphenylsilyl geschützt sein kann.
4. Verbindung oder Salz davon nach Anspruch 1, wobei R⁴ Phenoxyethyl ist.
5. Verbindung oder Salz davon nach Anspruch 1, wobei R¹ Trityl, 4-Methoxytrityl, 4-Methyltrityl, 4,4'-Dimethyltrityl, 4,4'-Dimethoxytrityl oder 4,4',4''-Trimethyltrityl ist.
6. Verbindung aus den folgenden (1) bis (3) oder ein Salz davon:

- (1) N⁹-[(2R,6S)-6-[(tert-Butyldimethylsilyloxy)methyl]-4-tritylmorpholin-2-yl]-N²-(phenoxyacetyl)-O⁶-(2-cyanoethyl)guanin,
- (2) N⁹-[(2R,6S)-6-hydroxymethyl-4-tritylmorpholin-2-yl]-N²-(phenoxyacetyl)-O⁶-(2-cyanoethyl)guanin,
- (3) [(2S,6R)-6-{N²-(phenoxyacetyl)-O⁶-(2-cyanoethyl)guanin-9-yl}-4-tritylmorpholin-2-yl]methyl-dimethylphosphoramidochloridat.

Revendications

1. Composé représenté par la formule générale (1) suivante ou l'un de ses sels :


[C.1]



(1)

dans laquelle R¹ représente un atome d'hydrogène ou un groupe représenté par la formule générale (2) suivante :



[C.2]



(2)

(dans laquelle * représente la position de liaison ;
R¹¹, R¹², R¹³ sont identiques ou différents et chacun représente un atome d'hydrogène, un groupe alkyle ou alcoxy)
R² représente un groupe représenté par la formule générale (3) ou (4) suivante :

[C.3]




(dans lesquelles * est défini comme il a été décrit ci-dessus :

R⁴ représente un groupe alkyle, arylméthyle ou aryloxyméthyle ;

R⁵, R⁶ sont identiques ou différents et chacun représente un groupe alkyle)

R³ représente un groupe hydroxy qui peut être protégé par un groupe trialkylsilyle ou diphénylalkylsilyle, ou un groupe représenté par la formule générale (5) suivante :

[C.4]



(dans laquelle * est défini comme il a été décrit ci-dessus ;

X représente O ou S ;

Y représente un groupe dialkylamino ou alcoxy ;

Z représente un atome d'halogène).


2. Composé ou l'un de ses sels selon la revendication 1, dans lequel X représente O, Y représente un groupe dialkylamino, et Z représente un atome de chlore.
3. Composé ou l'un de ses sels selon la revendication 1, dans lequel R³ représente un groupe hydroxy qui peut être protégé par un groupe t-butyl-diméthylsilyle ou t-butyl-diphénylsilyle.
4. Composé ou l'un de ses sels selon la revendication 1, dans lequel R⁴ représente un groupe phénoxy-méthyle.
5. Composé ou l'un de ses sels selon la revendication 1, dans lequel R¹ représente un groupe trityle, 4-méthoxytrityle, 4-méthyltrityle, 4,4'-diméthyltrityle, 4,4'-diméthoxytrityle, ou 4,4',4"-triméthyltrityle.
6. Composé choisi parmi les (1) à (3) suivants, ou l'un de leurs sels :

(1) N⁹-[(2R,6S)-6-[(tert-butyl-diméthylsilyloxy)méthyl]-4-tritylmorpholin-2-yl]-N²-(phénoxyacétyl)-O⁶-(2-cyanoéthyl)guanine,


(2) N⁹-[(2R,6S)-6-hydroxyméthyl-4-tritylmorpholin-2-yl]-N²-(phénoxyacétyl)-O⁶-(2-cyanoéthyl)guanine,

(3) diméthylphosphoramidochloridate de [(2S,6R)-6-{N²-phénoxyacétyl}-O⁶-(2-cyanoéthyl)guanine-9-yl]-tritylmorpholin-2-yl]méthyle.


[Figure 1]




[Figure 2]



[Figure 3]



[Figure 4]



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 2009064471 A1 [0005] [0124]
- WO 2009064471 A [0025] [0043] [0050] [0136]
- WO 1991009033 A [0043] [0071]
- WO 199109033 A [0093]

Non-patent literature cited in the description

- **ALUL.** *Nucleic Acids Research*, 1991, vol. 19, 1527 [0052]
- **WRIGHT.** *Tetrahedron Letters*, 1993, vol. 34, 3373 [0052]
- *Org. Lett.*, 2004, vol. 6 (15), 2555-2557 [0101]


Morfolino-nukleinsav származékok

Szabadalmi igénypontok



1. (1):


[C.1]



(1)

általános képletű vegyület vagy sója, ahol R¹ jelentése hidrogénatom vagy egy (2):

[C.2]



(2)


képletű csoport,

(ahol * a kapcsolódás helyét jelenti;


R^{11} , R^{12} , R^{13} azonos vagy eltérő, és mindegyik jelentése hidrogénatom, alkil vagy alkoxycsoport)

R^2 egy (3) vagy (4):

[C.3]



(3)



(4)

általános képletű csoport,


(ahol * jelentése a fenti;

R^4 alkil, arilmetil vagy ariloximetilcsoport;

R^5 , R^6 azonos vagy eltérő, és mindegyik jelentése alkilcsoport)

R^3 hidroxycsoport, mely trialkilszilil vagy difenilalkilszililcsoporttal lehet szubsztituált, vagy egy (5):

[C.4]



(5)

általános képletű csoport,

(ahol * jelentése a fenti;

X jelentése O vagy S;

Y dialkilamino vagy alkoxycsoport;

Z jelentése halogénatom).

2. Az 1. igénypont szerinti vegyület vagy sója, ahol X jelentése O, Y dialkylaminocsoport, és Z klóratom.

3. Az 1. igénypont szerinti vegyület vagy sója, ahol R^3 hidroxicsoport, mely terc-butildimetilszilil vagy terc-butildifenilszililesoporttal lehet szubsztituált.

4. Az 1. igénypont szerinti vegyület vagy sója, ahol R^4 fenoximetilesoport.

5. Az 1. igénypont szerinti vegyület vagy sója, ahol R^1 tritil, 4-metoxitritil, 4-metiltritil, 4,4'-dimetiltritil, 4,4'-dimetoxitritil, vagy 4,4',4''-trimetiltritilcsoport.

6. Az (1)-(3) vegyületek vagy sóik:

(1) N^9 -[(2R,6S)-6-((terc-butildimetilszililoxi)metil)-4-tritilmorfolin-2-il]- N^2 -(fenoxiacetil)- O^6 -(2-cianoetil)-guanin,

(2) N^9 -[(2R,6S)-6-hidroximetil-4-tritilmorfolin-2-il]- N^2 -(fenoxiacetil)- O^6 -(2-cianoetil)guanin,

(3) [(2S,6R)-6-({ N^2 -(fenoxiacetil)- O^6 -(2-cianoetil)guanin-9-il}-4-tritilmorfolin-2-il)metil dimetilfoszfóroamidokloridát

közül választott vegyület.

Szentpáteri Eszter
 Szakadalmi Gyűjtő
 SSGK Szakadalmi Gyűjtői Iroda
 H-1062 Budapest, Városház utca 113.
 Telefon: +36 1 361 1099 Fax: +36 1 1099
 e-mail: szentpateri_ssgk@sgk.hu